{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:05:54Z","timestamp":1791338754815,"version":"4.3.1"},"reference-count":59,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Philadelphia chromosome\u2013negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and the prefibrotic form of primary myelofibrosis (PMF), frequently progress to more overt forms of MF and a type of acute leukemia termed MPN-accelerated phase\/blast phase (MPN-AP\/BP). Recent evidence indicates that dysregulation of the tumor suppressor tumor protein p53 (TP53) commonly occurs in the MPNs. The proteins MDM2 and MDM4 alter the cellular levels of TP53. We investigated in 1,294 patients whether abnormalities involving chromosomes 1 and 12, which harbor the genes for MDM4 and MDM2, respectively, and chromosome 17, where the gene for TP53 is located, are associated with MPN disease progression. Gain of 1q occurred not only in individuals with MPN-BP but also in patients with PV and ET, who, with further follow-up, eventually evolve to either MF and\/or MPN-BP. These gains of 1q were most prevalent in patients with a history of PV and those who possessed the JAK2V617F driver mutation. The gains of 1q were accompanied by increased transcript levels of MDM4. In contrast, 12q chromosomal abnormalities were exclusively detected in patients who presented with MF or MPN-BP, but were not accompanied by further increases in MDM2\/MDM4 transcript levels. Furthermore, all patients with a loss of 17p13, which leads to a deletion of TP53, had either MF or MPN-AP\/BP. These findings suggest that gain of 1q, as well as deletions of 17p, are associated with perturbations of the TP53 pathway, which contribute to MPN disease progression.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018024018","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T16:54:16Z","timestamp":1545152056000},"page":"3581-3589","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6175","authenticated-orcid":false,"given":"Bridget K.","family":"Marcellino","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Division of Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Division of Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-1081","authenticated-orcid":false,"given":"Joseph","family":"Tripodi","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Division of Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Kosiorek","sequence":"additional","affiliation":[{"name":"Division of Health Science Research, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Division of Hematology\/Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[{"name":"Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou","family":"Dueck","sequence":"additional","affiliation":[{"name":"Division of Health Science Research, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Najfeld","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Division of Hematology\/Oncology, and"},{"name":"Department of Pathology, The Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"7","key":"2020021109102374200_B1","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2020021109102374200_B2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.thj.6200250","article-title":"Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy","volume":"4","author":"Kiladjian","year":"2003","journal-title":"Hematol J"},{"issue":"10","key":"2020021109102374200_B3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"2","key":"2020021109102374200_B4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"2020021109102374200_B5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"2020021109102374200_B6","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2020021109102374200_B7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/asheducation-2016.1.552","article-title":"Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions","volume":"2016","author":"Shammo","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2020021109102374200_B8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/jcmm.13095","article-title":"Epigenetics in myeloproliferative neoplasms","volume":"21","author":"McPherson","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2020021109102374200_B9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"7","key":"2020021109102374200_B10","first-page":"946","article-title":"Mutations in the P53 and RAS family genes are associated with tumor progression of BCR\/ABL negative chronic myeloproliferative disorders","volume":"7","author":"Gaidano","year":"1993","journal-title":"Leukemia"},{"issue":"5","key":"2020021109102374200_B11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"2020021109102374200_B12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020021109102374200_B13","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.2016.152363","article-title":"Genomic analysis of myeloproliferative neoplasms in chronic and acute phases","volume":"102","author":"Courtier","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2020021109102374200_B14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"15","key":"2020021109102374200_B15","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"50","key":"2020021109102374200_B16","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"2020021109102374200_B17","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1038\/onc.2016.478","article-title":"Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera","volume":"36","author":"Tsuruta-Kishino","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"2020021109102374200_B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-12-0053","article-title":"Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy","volume":"19","author":"Li","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2020021109102374200_B19","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2020021109102374200_B20","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2020021109102374200_B21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/onc.2011.313","article-title":"JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms","volume":"31","author":"Nakatake","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"2020021109102374200_B22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"2020021109102374200_B23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2020021109102374200_B24","first-page":"224","article-title":"Karyotype and molecular cytogenetic studies in polycythemia vera","volume":"4","author":"Andrieux","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"12","key":"2020021109102374200_B25","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3109\/10428194.2013.784970","article-title":"Significance of cytogenetic abnormalities in patients with polycythemia vera","volume":"54","author":"Sever","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2020021109102374200_B26","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"2020021109102374200_B27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2002.03763.x","article-title":"Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected","volume":"119","author":"Najfeld","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2020021109102374200_B28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2141.2010.08355.x","article-title":"Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia","volume":"151","author":"Najfeld","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021109102374200_B29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2020021109102374200_B30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2017.165795","article-title":"Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera","volume":"102","author":"Tang","year":"2017","journal-title":"Haematologica"},{"issue":"20","key":"2020021109102374200_B31","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2020021109102374200_B32","article-title":"Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase [published online ahead of print 4 April 2018]","author":"Mollard","journal-title":"Leuk Lymphoma"},{"key":"2020021109102374200_B33","first-page":"149","author":"McGowan-Jordan","year":"2016"},{"issue":"10","key":"2020021109102374200_B34","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2018.193763","article-title":"Genomic characterization of spleens in patients with myelofibrosis","volume":"103","author":"Zimran","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"2020021109102374200_B35","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.3324\/haematol.2016.142935","article-title":"Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation","volume":"101","author":"Kucine","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"2020021109102374200_B36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1755-8166-6-59","article-title":"Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease","volume":"6","author":"Singh","year":"2013","journal-title":"Mol Cytogenet"},{"issue":"4","key":"2020021109102374200_B37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109102374200_B38","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2020021109102374200_B39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/10428194.2016.1272689","article-title":"+1q: amplifying the bad genes in myeloma","volume":"58","author":"Chakraborty","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2020021109102374200_B40","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2020021109102374200_B41","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1182\/blood.V112.11.3640.3640","article-title":"Gain of 1q as a potential adverse prognostic marker in myelodysplastic syndrome: comparison with International Prognostic Scoring System variables","volume":"112","author":"Park","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020021109102374200_B42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cancergencyto.2008.05.003","article-title":"Pattern of trisomy 1q in hematological malignancies: a single institution experience","volume":"186","author":"Djordjevi\u0107","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"16","key":"2020021109102374200_B43","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2013-12-546077","article-title":"Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease","volume":"123","author":"Sawyer","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021109102374200_B44","doi-asserted-by":"crossref","first-page":"933","DOI":"10.18632\/oncotarget.1559","article-title":"High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia","volume":"5","author":"Tan","year":"2014","journal-title":"Oncotarget"},{"issue":"11","key":"2020021109102374200_B45","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2020021109102374200_B46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021109102374200_B47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2020021109102374200_B48","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2020021109102374200_B49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cancergencyto.2007.03.009","article-title":"Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes","volume":"176","author":"Etienne","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"2020021109102374200_B50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.leukres.2015.01.012","article-title":"Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities","volume":"39","author":"Benton","year":"2015","journal-title":"Leuk Res"},{"issue":"1","key":"2020021109102374200_B51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0165-4608(02)00554-X","article-title":"Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia","volume":"137","author":"Andrieux","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"7","key":"2020021109102374200_B52","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/sj.leu.2404700","article-title":"Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation","volume":"21","author":"Ohyashiki","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"2020021109102374200_B53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.10297","article-title":"Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia","volume":"39","author":"Andrieux","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"issue":"15","key":"2020021109102374200_B54","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2017004457","article-title":"Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms","volume":"1","author":"Ueda","year":"2017","journal-title":"Blood Adv"},{"issue":"7","key":"2020021109102374200_B55","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2016-12-757344","article-title":"Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-\u03b21 and Cxcl12 pathways","volume":"130","author":"Dutta","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2020021109102374200_B56","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"2020021109102374200_B57","first-page":"254","article-title":"Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia","volume":"130","author":"Mascarenhas","year":"2017","journal-title":"Blood"},{"issue":"36","key":"2020021109102374200_B58","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"2020021109102374200_B59","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/onc.2016.361","article-title":"Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting","volume":"36","author":"Wachter","year":"2017","journal-title":"Oncogene"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3581\/1554999\/advances024018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3581\/1554999\/advances024018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:46:43Z","timestamp":1581414403000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/24\/3581\/15985\/Advanced-forms-of-MPNs-are-accompanied-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":59,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018024018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734684232.793564985","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]}}}